12.02.2014 • News

Gallus BioPharmaceuticals appoints Claudette Kile as Vice President of Quality & Regulatory

Gallus BioPharmaceuticals, a premier pure-play biologics contract manufacturing organization (CMO) announces the appointment of Claudette Kile as Vice President of Quality & Regulatory. This addition to the Gallus leadership team supports the continued growth of the organization's contract manufacturing services.

Claudette Kile will be responsible for the planning, implementation and daily operations of the Quality & Regulatory organization at Gallus HQ in St. Louis and the Princeton, New Jersey facility.

"Gallus has a strong track record in process development, clinical and commercial manufacturing of licensed biopharmaceuticals at both sites, and the addition of Claudette Kile to our team strengthens our commitment to maintaining exemplary compliance for our pharma and biotech clients as their products mature through the clinic towards licensure" stated Mark Bamforth, President and CEO of Gallus.

Ms. Kile brings 27 years of industry experience in medical devices, biologics, and pharmaceuticals, with specialized expertise in building global compliant quality systems. She has experience with all phases of clinical trials and strong leadership, risk-based decision making, flexibility, compliance, project management, and organizational skills.

Most recently, Ms. Kile was Senior Director of Quality at Jazz Pharmaceuticals where she led the oversight of global clinical trials and drug safety and pharmacovigilance activities. Previous roles in Quality include; Director, Quality Assurance at Emergent Biosolutions, where she oversaw the supply of vaccines and antibody therapy products from pre-clinical through commercial and managing her own consultancy focusing on regulatory affairs, compliance, and quality assurance. Earlier in her career, Ms. Kile held roles with increasing responsibility at Abbott Labs, as Director, Global Clinical Quality, EV3, Inc. (now part of Covidien) and an extended period at Guidant where she managed 4 clinical departments and had a variety of hands-on quality roles.

Company

Gallus Biopharmaceuticals, LLC

4766 LaGuardia Drive
63134-3117 St. Louis

Company contact







Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

most read